ORIGIN trial shows safety and efficacy of insulin glargine

摘要

The ORIGIN trial, a large trial in patients with high cardiovascular risk and dysglycaemia, using an intervention of initial basal insulin (glargine) in impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or early-stage type 2 diabetes, has shown no cardiovascular benefits or adverse cardiovascular outcomes. However a reduction of progression to diabetes did occur in patients with IFG or IGT who were treated with insulin, actively targeting normoglycaemia of < 5.3 mmol/l, compared to those treated with standard care and mainly oral agents.